Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This study suggests that nephronectin (NPNT) could serve as a novel prognostic marker for poor prognosis in a subgroup of breast cancer patients, associated with specific NPNT staining patterns.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

In this study, combining L-cysteine and N-acetylcysteine with MET inhibition enhanced cytotoxicity in cancer cell lines by sensitizing them to MET inhibition through redox stabilization, suggesting a promising approach for improving MET-targeted cancer therapies without additional oxidative or chemotherapeutic stress.

In this study, researchers observed that nestin-expressing cells in mice can differentiate into blood-vessel-like and nerve-like structures within human melanoma tumors, while bevacizumab treatment altered the origin of these structures to trans-differentiated melanoma cells without significantly impacting tumor growth.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

This case study reports a unique and severe papulopustular eruption, likely induced by sorafenib treatment in a patient with metastatic renal cancer, which manifested as hyperkeratotic spicules and improved with cessation of the drug.

In this study, the researchers developed a novasome vesicle carrying bovine placenta extract, which demonstrated superior hair growth effects in rats compared to traditional minoxidil and PE-loaded liposomes, and showed good stability and physical characteristics over 90 days at 4°C.

Nephronectin is linked to worse outcomes in breast cancer and helps cancer spread.

This review discusses the side effects associated with ovarian cancer treatment and highlights the need for tools to assess, prevent, and manage these effects; it reports no clinical results.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

In this study, a validated chromatographic method demonstrated the ability to simultaneously analyze gemcitabine and olaparib in pancreatic cancer tissues, supporting the advancement of pharmaceutical formulations combining these drugs, particularly for patients with BRCA mutations.

This case report describes a 49-year-old woman with metastatic adrenocortical carcinoma in the liver who experienced an abscopal effect after pulse electric field ablation, with PET/CT imaging showing complete resolution of three untreated lesions two months post-treatment.

This study found that the computer-controlled RV-01 scalp cooling device helped prevent significant hair loss in metastatic breast cancer patients treated with eribulin, with none of the 16 patients requiring a wig and experiencing minimal discomfort.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.